
CAI (CAI) Stock Forecast & Price Target
CAI (CAI) Analyst Ratings
Bulls say
Caris Life Sciences is supported by a leading precision-oncology platform with strong underlying demand, as Q3'26 revenue of $275M rose 27% Y/Y, Adj. EBITDA reached $44M, and cash stood at $769M while volumes climbed to 61.5k cases and blended ASPs improved to about $4,272 per test. Its outlook is strengthened by durable share gains in a market still under-penetrated at roughly 30%, expanded payer coverage, and a large sales force of 325 that should keep supporting case growth and mix-shift toward higher-reimbursed tests like MI Cancer Seek. Additional upside comes from pipeline catalysts including Caris Confirm MRD launching in December and Caris Detect entering early screening, while a raised 2026 revenue guide of $1.04B-$1.05B and a path to stronger ASPs reinforce operating leverage.
Bears say
Caris Life Sciences is facing a challenging fundamental setup because slower-than-expected revenue contribution from Caris Assure and broader competitive pressure in precision oncology could limit near-term growth, especially against large established rivals in tissue, blood, MRD, and screening diagnostics. Reimbursement and contracting remain uncertain, while the company’s newer products carry commercialization risk despite its successful tissue test history; its early Detect launch looks particularly fragile at $3,500 per test with no insurance coverage, no FDA clearance, and a small, high-risk study base of just above 3,000 participants. It also faces valuation volatility, potential litigation, and modest balance sheet risk if additional capital is needed to fund expansion into MRD and early cancer detection.
This aggregate rating is based on analysts' research of CAI and is not a guaranteed prediction by Public.com or investment advice.
CAI (CAI) Analyst Forecast & Price Prediction
Start investing in CAI (CAI)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About CAI (CAI) Forecast
CAI (CAI) Analyst Forecast & Price Prediction
Start investing in CAI (CAI)
Order type
Buy in
Order amount
Est. shares
0 shares